Mary Ruwart, who recently left the company along with Kubby, thinks that Cannabis Science might be putting the cart before the horse. The preliminary studies required to apply for FDA clinical trials take months to complete, she said, and "since these studies were not even on the drawing board when I left three weeks ago, they cannot have been completed."
When asked about this publicity, Kubby said he finds it "damaging to the mission" and feels that Cannabis Science is "not playing by the rules," by publicizing the talks as though the FDA were already onboard.
Though no longer with the company, Kubby plans to continue his work on the lozenge, which he claimed he has the exclusive rights to.
"It's a mystery to me how [Cannabis Science] think[s] they are going to use this technology," he said.
But Melamede denied this, maintaining that the rights are the property of the company and hence are his to develop. Either way, both men are moving forward with the technology in the coming months, but it will be a couple years -- if at all -- before edible products like the cannabis lozenge make it through the FDA's clinical trials.
Whether marijuana will make the shift from being smoked in the parking lot of the corner drugstore to gracing its shelves remains unknown.
One thing, however, is clear: Smoking marijuana in lieu of the lozenge likely will do much more harm than good if you happen to have a respiratory infection -- not to mention that smoking anything is damaging to someone with flu-related respiratory ills.
As Horovitz put it, "No doctor in his right mind would tell a flu patient to go smoke a joint."